Faruqi & Faruqi Encourages Aldeyra Investors to Reach Out
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 03 2026
0mins
Should l Buy ALDX?
Source: PRnewswire
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Aldeyra Therapeutics, Inc., particularly for investors who purchased or acquired securities between November 3, 2023, and March 16, 2026, indicating concerns over the company's future legal liabilities.
- Investor Rights Reminder: The firm reminds investors that May 29, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance and urgency of investor participation in legal proceedings.
- Direct Contact Channels: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a convenient avenue for legal support.
- Potential Loss Warning: Due to the ongoing investigation, investors may face potential financial losses, indicating possible undisclosed risks within the company, prompting investors to carefully reassess their investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.780
Low
9.00
Averages
9.50
High
10.00
Current: 1.780
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Aldeyra Therapeutics Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that they must apply to be lead plaintiff by May 29, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which minimizes financial risk for investors by ensuring they only pay if the case is successful.
- Lawsuit Background: The lawsuit alleges that during the class period, Aldeyra's management made false and misleading statements and failed to disclose inconsistencies in the clinical trial results of its drug candidate reproxalap, leading to investor losses when the true information was revealed.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and influence in the field.
See More
Aldeyra Faces Class Action Lawsuit Following FDA Response
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Aldeyra Therapeutics, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 29, 2026, indicating significant legal risks that could impact the company's reputation and shareholder confidence.
- Adverse FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA stating that its New Drug Application lacked sufficient evidence of efficacy, presenting major regulatory challenges that could hinder future drug approval plans and market entry.
- Stock Price Plunge: Following the FDA news, Aldeyra's stock price fell by $2.99, a staggering 70.69% drop, closing at $1.24, reflecting a pessimistic market outlook on the company's future and potentially leading to further erosion of investor confidence.
- Law Firm Credentials: Pomerantz LLP is a prominent class action law firm with a strong focus on corporate and securities litigation, boasting a rich history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its formidable presence and influence in the legal landscape.
See More
Faruqi & Faruqi Encourages Aldeyra Investors to Discuss Legal Options
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Aldeyra Therapeutics, Inc., particularly for investors who purchased or acquired securities between November 3, 2023, and March 16, 2026, indicating a serious focus on investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310), aiming to assist investors in understanding their legal rights.
- Class Action Reminder: The firm reminds investors that May 29, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against Aldeyra, emphasizing the urgency of the legal process.
- Potential Market Impact: Due to the ongoing legal investigation, Aldeyra's stock price may face negative pressure, prompting investors to monitor developments closely to assess their investment risks.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that they must apply to be lead plaintiff by May 29, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Class Action Reminder for Aldeyra Therapeutics Investors
- Class Action Initiated: Robbins LLP reminds all investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that a class action has been filed, alleging the company misled investors regarding clinical trial results, potentially leading to significant investor losses.
- Inconsistent Clinical Trial Results: The lawsuit claims that Aldeyra failed to disclose inconsistencies in the clinical trial results for its lead drug candidate reproxalap, rendering any positive findings unreliable and affecting the credibility of the company's business and prospects, which may diminish investor confidence in the company's future.
- Stock Price Plummet: Following the receipt of a Complete Response Letter from the SEC on March 17, 2026, indicating a lack of substantial evidence for the drug's efficacy, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share, reflecting extreme market pessimism regarding the company's outlook.
- Shareholder Action Recommended: Investors are encouraged to submit their papers by May 29, 2026, to serve as lead plaintiffs in the class action, although they can still recover without participating, indicating that shareholders have opportunities to protect their rights amidst this situation.
See More
Class Action Lawsuit Filed Against Aldeyra Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Aldeyra Therapeutics and certain executives, seeking damages for investors who purchased securities between November 3, 2023, and March 16, 2026, reflecting strong investor concerns over potential fraud.
- Allegations Details: The complaint alleges that defendants made false or misleading statements during the class period and failed to disclose inconsistencies in clinical trial results for the drug candidate reproxalap, leading to misjudgments about the company's prospects and impacting stock price stability.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by May 29, 2026, to share in any potential recovery, indicating active participation and advocacy for their rights within the legal process.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC will represent investors on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thus reducing financial risk for investors and encouraging more victims to join the lawsuit.
See More
Reminder for Aldeyra Therapeutics Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that they must apply to be lead plaintiff by May 29, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which minimizes financial risk for investors by ensuring they only pay if the case is successful.
- Lawsuit Background: The lawsuit alleges that during the class period, Aldeyra's management made false and misleading statements and failed to disclose inconsistencies in the clinical trial results of its drug candidate reproxalap, leading to investor losses when the true information was revealed.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its expertise and influence in the field.
See More
Aldeyra Faces Class Action Lawsuit Following FDA Response
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Aldeyra Therapeutics, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 29, 2026, indicating significant legal risks that could impact the company's reputation and shareholder confidence.
- Adverse FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA stating that its New Drug Application lacked sufficient evidence of efficacy, presenting major regulatory challenges that could hinder future drug approval plans and market entry.
- Stock Price Plunge: Following the FDA news, Aldeyra's stock price fell by $2.99, a staggering 70.69% drop, closing at $1.24, reflecting a pessimistic market outlook on the company's future and potentially leading to further erosion of investor confidence.
- Law Firm Credentials: Pomerantz LLP is a prominent class action law firm with a strong focus on corporate and securities litigation, boasting a rich history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its formidable presence and influence in the legal landscape.
See More
Faruqi & Faruqi Encourages Aldeyra Investors to Discuss Legal Options
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Aldeyra Therapeutics, Inc., particularly for investors who purchased or acquired securities between November 3, 2023, and March 16, 2026, indicating a serious focus on investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310), aiming to assist investors in understanding their legal rights.
- Class Action Reminder: The firm reminds investors that May 29, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against Aldeyra, emphasizing the urgency of the legal process.
- Potential Market Impact: Due to the ongoing legal investigation, Aldeyra's stock price may face negative pressure, prompting investors to monitor developments closely to assess their investment risks.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that they must apply to be lead plaintiff by May 29, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Class Action Reminder for Aldeyra Therapeutics Investors
- Class Action Initiated: Robbins LLP reminds all investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that a class action has been filed, alleging the company misled investors regarding clinical trial results, potentially leading to significant investor losses.
- Inconsistent Clinical Trial Results: The lawsuit claims that Aldeyra failed to disclose inconsistencies in the clinical trial results for its lead drug candidate reproxalap, rendering any positive findings unreliable and affecting the credibility of the company's business and prospects, which may diminish investor confidence in the company's future.
- Stock Price Plummet: Following the receipt of a Complete Response Letter from the SEC on March 17, 2026, indicating a lack of substantial evidence for the drug's efficacy, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share, reflecting extreme market pessimism regarding the company's outlook.
- Shareholder Action Recommended: Investors are encouraged to submit their papers by May 29, 2026, to serve as lead plaintiffs in the class action, although they can still recover without participating, indicating that shareholders have opportunities to protect their rights amidst this situation.
See More
Class Action Lawsuit Filed Against Aldeyra Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Aldeyra Therapeutics and certain executives, seeking damages for investors who purchased securities between November 3, 2023, and March 16, 2026, reflecting strong investor concerns over potential fraud.
- Allegations Details: The complaint alleges that defendants made false or misleading statements during the class period and failed to disclose inconsistencies in clinical trial results for the drug candidate reproxalap, leading to misjudgments about the company's prospects and impacting stock price stability.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by May 29, 2026, to share in any potential recovery, indicating active participation and advocacy for their rights within the legal process.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC will represent investors on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thus reducing financial risk for investors and encouraging more victims to join the lawsuit.
See More
